HUSSMAN STRATEGIC ADVISORS, INC.
Position in PHAT — Phathom Pharmaceuticals, Inc.
CIK 1179475
ELLICOTT CITY, MD
Position in PHAT
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$933,240
-$1,505,490 QoQ
Shares Held
84,000
-42.9% QoQ
Ownership
0.104%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PHAT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HUSSMAN STRATEGIC ADVISORS, INC. holds $44,525,983 across 23 Biotechnology names. PHAT ranks #20 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CORT |
Corcept Therapeutics Inc
|
126,000 | $5,079,060 | |
| 2 | ACAD |
Acadia Pharmaceuticals Inc
|
168,000 | $3,739,680 | |
| 3 | INVA |
Innoviva, Inc.
|
147,000 | $3,425,100 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
52,500 | $3,393,075 | |
| 5 | INCY |
Incyte Corp
|
31,500 | $2,964,780 | |
| 6 | STOK |
Stoke Therapeutics, Inc.
|
84,000 | $2,735,040 | |
| 7 | SEPN |
Septerna, Inc.
|
105,000 | $2,523,150 | |
| 8 | HRMY |
Harmony Biosciences Holdings, Inc.
|
84,000 | $2,352,840 |
All Filings in PHAT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $933,240 | 84,000 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $2,438,730 | 147,000 | Shares | Sole | 2026-02-02 | |
| No filing history on record for this holder in this stock. | ||||||